Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639928 | 0.90 | TSHR (0.50) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL1834351 | 0.90 | TSHR (0.50) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL475639 | 0.90 | TSHR (0.50) | TSHRKMT2AGAANPBWR1NPSR1 | |
| Bromide SCHEMBL7457265 | 0.88 | TSHR (0.49) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL3300446 | 0.88 | TSHR (0.49) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL18085379 | 0.88 | TSHR (0.49) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL7925104 | 0.88 | TSHR (0.49) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL3300438 | 0.88 | TSHR (0.49) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL18085353 | 0.85 | TSHR (0.46) | TSHRKMT2AGAANPBWR1NPSR1 | |
| SCHEMBL1543705 | 0.85 | TSHR (0.50) | TSHRKMT2AGAANPBWR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133234-A1 | SORTILIN BINDERS AND BIFUNCTIONAL COMPOUNDS THEREOF | DRAUPNIR BIO APS (DK) | 2025-06-26 | — | — | WO | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-109280046-B | Benzimidazole derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9623046-B2 | Amphiphilic Janus-dendrimers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| EP-2846804-A2 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169704-A2 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120308640-A1 | AMPHIPHILIC JANUS-DENDRIMERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011017500-A1 | AMPHIPHILIC JANUS-DENDRIMERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORC, RORB, RORA | TSHR 356/4885KMT2A 2343/4885GAA 2944/4885 |
| US-20120308640-A1 | AMPHIPHILIC JANUS-DENDRIMERS | OR10J3, H1-10, CXCR3 | TSHR 852/4885KMT2A 2299/4885GAA 4643/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | TSHR 331/4885KMT2A 1974/4885GAA 520/4885 |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | TSHR 1268/4885KMT2A 1458/4885GAA 249/4885 |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | TSHR 356/4885KMT2A 2343/4885GAA 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.